secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oncology Institute, Inc. (TOI)
CIK:        0001799191
Form:       8-K
Filed at:   2026-09-02T00:41:15+00:00
Accession:  0001079973-26-001208
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Starling Oncology director Brad Hively to step down as Vice Chairman, not seek re-election
--------------------------------------------------------------------------------

- On Sept 1, 2026, Brad Hively notified Starling Oncology he will not stand for re-election at the 2027 annual meeting.
- Hively remains a director until the annual meeting but immediately relinquishes Vice Chairman and committee roles.
- Company states his decision is not due to any disagreement with operations, policies, or practices.
- No replacement named; board composition change effective at 2027 annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799191/000107997326001208/0001079973-26-001208-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799191/000107997326001208/stln_8k.htm
  HTML page:      https://secwatch.observer/filing/0001079973-26-001208

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer